CASE REPORT article
Front. Oncol.
Sec. Thoracic Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1645580
Remarkable Tumor Response to Iruplinalkib in a 14-Year-Old Girl With ALK-Positive Advanced Metastatic Non-Small-Cell Lung Cancer: A Case Report
Provisionally accepted
Jiahao Wang
Qingdi DuXueyan SunRong TaoZuojuan ZhangWei LiWenjing LiuLi Wei*Zongsheng Tian*Xueliang Xu*- Linyi People's Hospital, Linyi, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Targeted therapies for anaplastic lymphoma kinase (ALK) mutations in non-small cell lung cancer (NSCLC) generally extend survival and alleviate symptoms. However, significant tumor reduction or complete remission remains rare. We report a rare case 2 of a 14-year-old girl, whose father and grandfather both had lung cancer, diagnosed with advanced, multi-site metastatic ALK-positive NSCLC. She was treated with Iruplinalkib, a newly approved targeted therapy in China, resulting in remarkable tumor shrinkage. The patient presented with severe symptoms, including persistent cough, pain, and hemoptysis. A lung CT scan revealed a large mass, which was pathologically diagnosed as pulmonary adenocarcinoma. After initiating Iruplinalkib therapy, the primary tumor rapidly decreased in size by 80.3%, from 132 mm × 97 mm to 26 mm × 21 mm, within one month. Most metastatic lesions also showed significant regression. By six months, the pulmonary tumor had almost disappeared. This case underscores the potential of Iruplinalkib, which is currently not available outside of China, to induce rapid and profound tumor regression in ALK-positive NSCLC, particularly in adolescent patients with aggressive clinical presentations. We hope that the anticancer efficacy of Iruplinalkib will be recognized globally and that it will become accessible to ALK-positive lung cancer patients worldwide.
Keywords: Non-small cell lung cancer, ALK fusion gene mutation, iruplinalkib, targeted therapy, case report
Received: 12 Jun 2025; Accepted: 07 Jul 2025.
Copyright: © 2025 Wang, Du, Sun, Tao, Zhang, Li, Liu, Wei, Tian and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Li Wei, Linyi People's Hospital, Linyi, China
Zongsheng Tian, Linyi People's Hospital, Linyi, China
Xueliang Xu, Linyi People's Hospital, Linyi, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.